🧬 Longevity

A $129 Million Bet That One Injection Can Replace 3,650 Cholesterol Pills

Scribe Therapeutics just IPO'd to fund a single epigenetic infusion that silences the cholesterol gene PCSK9 without cutting DNA. Eight days earlier, Merck launched the first oral PCSK9 pill at $315 a month. An original cost-per-decade analysis across five generations of cholesterol therapy reveals when one shot becomes cheaper than swallowing a pill every morning for ten years.

By Dr. Iris Blackwell · Longevity · July 29, 2026 · ☕ 9 min read

Ninety-three million American adults have LDL cholesterol above 130 mg/dL. For decades, they had one cheap option: a generic statin at roughly $4 a month. On July 16, Merck handed them a second path when the FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, priced at $315 per month, which cuts LDL by 56 to 59 percent in Phase 3 trials and roughly doubles what statins manage alone but also locks patients into $3,780 a year, every year, for the rest of their lives.

Eight days later, a company most cardiologists have never heard of raised $129 million on the Nasdaq to make both the pill and the injection obsolete.

Scribe Therapeutics (SCTX) priced its IPO at $15 on July 23 and began trading the next morning, surging 70 percent by lunch before settling at $18.75 by Monday in a reception that reveals how aggressively Wall Street now prices the gap between chronic therapy and a one-and-done cure for a pre-revenue biotech with no approved product, no Phase 2 data, and a market cap under $300 million.

What Scribe Actually Does

Scribe's lead candidate, STX-1150, does not cut DNA, and that distinction matters enormously. CRISPR Therapeutics and Verve (now owned by Eli Lilly) are both running Phase 1 trials that permanently edit the genome to knock out PCSK9. Scribe takes a fundamentally different route: its ELXR platform uses a CasX enzyme, engineered in Jennifer Doudna's lab at UC Berkeley, to attach chemical silencing marks to the PCSK9 gene without snipping or scarring it, leaving the gene intact but shutting down production of the protein that blocks LDL clearance from the bloodstream.

In non-human primate studies, a single intravenous infusion of STX-1150 reduced LDL cholesterol by more than 50 percent. Two years later, the effect held. It persists because the silencing marks copy themselves onto daughter cells whenever liver tissue divides. Scribe is now dosing up to 64 patients in a first-in-human Phase 1 trial in Australia, with initial results expected in the first half of 2027.

Reversibility is the sharpest marketing edge. Because the underlying DNA sequence remains unaltered, epigenetic silencing could theoretically be undone if a patient develops an unexpected adverse reaction years later. Permanent DNA edits offer no such escape hatch. Whether that distinction survives clinical reality remains an open question. But it is the reason Eli Lilly now owns 10.9 percent of Scribe's stock and Sanofi paid $7.5 million for a concurrent private placement.

The Cost-Per-Decade Ladder

Five generations of PCSK9-targeting cholesterol therapy now exist simultaneously. A $4 monthly generic at one end, a speculative one-time infusion at the other. Nobody has run the ten-year cost comparison across all five, so we built one.

*Non-human primate data; human clinical data expected H1 2027. Annual costs are U.S. list prices (WAC) before insurance rebates. Sources: Merck press release (Jul 16, 2026), Amgen 2025 annual report, Novartis investor relations, GoodRx.

The break-even math reveals itself instantly. If Scribe prices STX-1150 below $37,800 and the effect lasts ten years from one infusion, it beats a decade of daily Lipfendra pills on raw cost alone. Against Repatha's $58,500 cumulative tab, the ceiling is even higher. And this calculation ignores the compounding economic value of perfect adherence. Roughly half of statin patients stop taking their pills within a year, a dropout pattern that injectable PCSK9s only partly solved and that daily oral Lipfendra will likely reproduce.

A one-time infusion eliminates adherence as a variable entirely, because you cannot forget to take a drug that has already rewritten your liver cells and finished its work before you left the clinic.

The Addressable Market Is Smaller Than 93 Million

Treating all 93 million Americans with elevated LDL using a hypothetical $100,000 one-time infusion would cost $9.3 trillion. Nobody is proposing that. Generic atorvastatin at $48 a year works fine for most patients. Where the economics flip is the roughly 8.5 million Americans who are statin-intolerant (muscle pain, liver toxicity) or statin-inadequate (LDL still dangerously elevated despite maximum tolerated doses). Add 1.3 million with heterozygous familial hypercholesterolemia, where LDL is genetically locked high regardless of lifestyle.

So the real addressable pool is about 10 million patients. For someone who would otherwise spend $3,780 a year on Lipfendra for thirty working years, the lifetime drug cost reaches $113,400. A single infusion priced anywhere in the five-figure range becomes an obvious trade. Payers would jump at it.

Analyst consensus already projects Lipfendra will reach $5 billion in peak annual sales, largely by converting patients away from injectable PCSK9s. Scribe wants that revenue stream. If its human data match the primate results, it will be targeting Lipfendra's market before Merck has finished building it.

What This Analysis Cannot Tell You

Primate LDL data do not predict human safety. STX-1150's Phase 1 trial is dosing 64 patients in a dose-escalation design, and the most dangerous unknowns cluster around off-target epigenetic silencing where the CasX enzyme accidentally represses a gene the patient needs for normal liver function, immune reactions to either the CasX protein itself or the lipid nanoparticle delivery vehicle that ferries it into hepatocytes, and the long-term durability question that no one can answer until years of human follow-up accumulate. Two years of primate follow-up is encouraging but not a guarantee of ten-year persistence in human liver tissue.

Competition is fierce. CRISPR Therapeutics and Verve are running DNA-editing programs that permanently alter the genome, and base editing, which changes a single DNA letter without cutting both strands, may prove safer than Scribe's approach when Verve's Phase 1 data on PCSK9 base editing reads out around the same time as Scribe's next year, creating a direct head-to-head comparison that neither company controls.

Scribe is fragile. It has $36 million in collaboration revenue but zero product revenue. Its $129 million IPO funds roughly three to four years of operations, and if Phase 1 disappoints, there is no fallback because the XE gene-editing programs targeting Lp(a) and triglycerides trail STX-1150 by 12 to 18 months.

What You Can Do

If you are currently on a statin and your LDL is at goal, do nothing, because atorvastatin at $4 a month remains the most cost-effective cardiovascular intervention in medicine and no genetic therapy will change that calculus for patients whose cholesterol is already controlled. If you are statin-intolerant or your LDL stays above 100 mg/dL despite medication, ask your cardiologist about Lipfendra, which became available this month at roughly half the cost of injectable alternatives. For patients watching the genetic medicine horizon, mark the first half of 2027: that is when both Scribe's epigenetic silencing data and Verve's base-editing data will reveal whether one-shot cholesterol editing works in humans, and neither therapy is available outside clinical trials today.

The Bottom Line

Merck spent a decade and billions of dollars to move PCSK9 inhibition from an injection to a pill. Scribe raised $129 million to leapfrog both formats entirely and deliver the same effect as a single infusion that lasts years. The cost-per-decade math shows the break-even threshold is surprisingly forgiving: any one-time treatment priced under $37,800 beats ten years of daily Lipfendra. The question is no longer whether one-shot cholesterol editing is theoretically cheaper. It is whether epigenetic silencing works in humans without cutting their DNA, and we will have that answer within twelve months.